Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Approves Aastrom Phase III IND for Treatment of Osteonecrosis of the Femoral Head
Patient-Specific Stem Cell Trial to Address Unmet Medical Need
View HTML
Toggle Summary Webcast Alert: Aastrom Announces Its Third Quarter Investor Conference Call
ANN ARBOR, Mich., May 03, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year 2007 Investor Conference Call When: Tuesday, May 8, 2007 @ 9:00 am (EDT) Where:
View HTML
Toggle Summary Aastrom Initiates Adult Stem Cell Clinical Trial for Peripheral Arterial Disease
FDA-Approved Phase IIb Trial Underway in U.S. to Treat Critical Limb Ischemia
View HTML
Toggle Summary Aastrom to Present at Cowen & Company 27th Annual Health Care Conference
ANN ARBOR, Mich., March 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and
View HTML
Toggle Summary Aastrom's U.S. Clinical Investigator to Report Interim Data on Long Bone Fracture Repair Trial
-- Additional Positive Patient Treatment Results Presented at the American Academy of Orthopaedic Surgeons Meeting --
View HTML
Toggle Summary Aastrom Reports Second Quarter Fiscal Year 2007 Financial Results
ANN ARBOR, Mich., Feb 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today reported financial results for the second fiscal quarter ended December 31, 2006.
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences Announces Its Second Quarter Investor Conference Call
ANN ARBOR, Mich., Feb 02, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 2nd Quarter Fiscal Year 2007 Investor Conference Call When: Wednesday, February 7, 2007 @ 9:00 am (EST) Where:
View HTML
Toggle Summary Aastrom Receives Orphan Drug Designation from FDA for Dilated Cardiomyopathy
- Up to 150,000 People in U.S. Currently Suffer from this Severe Chronic Heart Disease
View HTML
Toggle Summary Aastrom Treats Patients in Adult Stem Cell Clinical Trial for Osteonecrosis
- Pivotal Bone Regeneration Trial Underway in Spain -
View HTML
Toggle Summary Sheldon A. Schaffer, Ph.D. Joins Aastrom As Vice President, Corporate Development & Intellectual Property
-- Appointment Supports New Initiatives --
View HTML

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.